Imspex Diagnostics recently partnered with the National Physical Laboratory (NPL), @KTNUK and @InnovateUK in their Analysis for Innovators (A4i) programme to investigate the utility of our GC-IMS technology combination for detecting and quantifying siloxanes from biomethane. This is an important collaboration, both from environmental and analytical method development perspectives. NPL will now propose GC-IMS as […]
Imspex is delighted to be part of the ground-breaking process analytical technologies (PAT) consortium announced today by the Cell and Gene Therapy Catapult. The consortium of over 20 pharmaceutical companies, technology providers, therapy developers and charities is the largest in the cell and gene therapy space to date with a mission to co-create industry-specific solutions […]
The Imspex Group’s proprietary gas chromatography-ion mobility spectrometry (GC-IMS) technology was part of a ground-breaking cancer detection study that was recently carried out by a team of researchers from the University of Warwick, Coventry University and the University of Leicester. In this study, the FlavourSpec® headspace analysis device showed that volatile organic compounds (VOCs) in […]
Human breath contains up to a thousand volatile organic compounds that, when analysed, can tell a story about a body’s state of health. These chemical compounds reflect the end processes of metabolic pathways. Patterns of compound peaks form ‘signatures’ when breath is analysed into its components and it is these signatures that allow for disease […]
A rapid and non-invasive test that can identify whether COVID-19 is present or not can make all the difference in giving people peace of mind to attend appointments for existing medical conditions or to get going again with business, education and sporting activities. This is one of the driving factors for the work of Dr […]
Imspex Diagnostics’ proprietary GC-IMS analytical technology platform has built a legacy of being a versatile, accurate and robust analytical research tool in situations where compound combinations are complex and/ or concentrations are low. Much of this legacy has centred around volatile compounds in industrial and more recently environmental and food production settings. The ultra-highly sensitive […]
Efforts to develop a quick and non-invasive breath test for the presence of COVID-19 are underway in Vancouver, British Columbia. Imspex’s BreathSpec® is one of a battery of tests that are being used by Dr Renelle Myers and her Vancouver Coastal Health team in their work to develop a breath test that identifies the possible […]
Antibiotic Resistance Antibiotic resistance has become an ever-growing concern for society today due to its increasing effect on mortality and morbidity. For many years now there has been a huge reliance on antibiotics and hence over prescription by healthcare professionals, and this has ultimately led to the growing problem of antibiotics losing their effectiveness on […]
Discover our stand-alone Ion Mobility Spectrometer The stand-alone IMS (Ion Mobility Spectrometer) by G.A.S. mbH enables the use of the IMS technology in very demanding gas phase applications where high separation capabilities and/or sensitivity are needed. Compared to other detectors the IMS offers a second dimension of separation and by that full orthoganality so that […]
Imspex Diagnostics’ patent portfolio recently grew, with news that the European Patent Office has granted the patent “Method for measuring human exhaled air”. This is the platform that is used to screen for disease indications such as bacterial and viral respiratory tract infections, Group B Streptococcus infection, lung cancer and other chronic inflammatory respiratory conditions. […]
The Imspex Group’s BreathSpec® technology is well-placed to play a leading role in combatting antimicrobial resistance by helping healthcare practitioners to differentiate between bacterial and viral causes of respiratory infection. This would better allow the right antibiotic to be prescribed to the right patient at the right time and in the right dose , thereby […]
Findings of a feasibility study into the potential for breath analysis to help doctors to differentiate between COVID-19 and other respiratory conditions were published in The Lancet on 24 October 2020. The Imspex Group’s BreathSpec® instrument showed clusters of breath compounds reflecting the effects of COVID-19’s multi-system nature. Similar clusters were found independently across research […]